Research map: Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars

Back to the article

Papers in this map

  1. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. · Désirée M F M van der Heijde · 1990 · 1088 citations · Cited by this paper
  2. Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period · 2026 · Related
  3. The Stanford Health Assessment Questionnaire: dimensions and practical applications. · Bonnie Bruce · 2003 · 817 citations · Cited by this paper
  4. Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening · 2026 · Related
  5. Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3 · Jesse A. Berlin · 2008 · 210 citations · Cited by this paper
  6. Timing of health technology assessment in the United States: An evaluation of ICER reviews over 8 years · 2026 · Related
  7. Race, Healthcare, and Health Disparities: A Critical Review and Recommendations for Advancing Health Equity · Wendy Macias‐Konstantopoulos · 2023 · 208 citations · Cited by this paper
  8. Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis · 2026 · Related
  9. The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology · Kelly A. Hirko · 2022 · 128 citations · Cited by this paper
  10. Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States · 2026 · Related
  11. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective · Pekka Kurki · 2021 · 98 citations · Cited by this paper
  12. Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study · 2026 · Related
  13. Regulation of biosimilar medicines and current perspectives on interchangeability and policy · J. O’Callaghan · 2018 · 89 citations · Cited by this paper
  14. Patient experience data in formulary decision-making: Payer-reported perceptions and use · 2026 · Related
  15. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics · David Charles Klonoff · 2019 · 77 citations · Cited by this paper
  16. Evaluating the design and implementation challenges of the Centers for Medicare & Medicaid Services’ Cell and Gene Therapy Access Model · 2026 · Related
  17. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration · Frank Gerhard Holz · 2021 · 70 citations · Cited by this paper
  18. US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriateness · 2026 · Related
  19. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020 · Bhakti Arondekar · 2021 · 66 citations · Cited by this paper
  20. Advancing the measurement of caregiver impact: Data collection priorities aligned with caregiver, health technology assessment, and policy stakeholders · 2026 · Related
  21. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? · Anna Hung · 2017 · 48 citations · Cited by this paper
  22. Are we ready to close the discussion on the interchangeability of biosimilars? · Hans C. Ebbers · 2019 · 45 citations · Cited by this paper
  23. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? · Daniel F. Alvarez · 2020 · 42 citations · Cited by this paper
  24. Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study · Thomas Blevins · 2019 · 36 citations · Cited by this paper
  25. Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies · Bo Huang · 2020 · 31 citations · Cited by this paper
  26. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial · Alan Menter · 2022 · 30 citations · Cited by this paper
  27. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment · Justin W. Timbie · 2021 · 29 citations · Cited by this paper
  28. Response Rate as an Approval End Point in Oncology · Gideon Michael Blumenthal · 2016 · 27 citations · Cited by this paper
  29. Social and Behavioral Variables in the Electronic Health Record: A Path Forward to Increase Data Quality and Utility · Elyse C. Lasser · 2021 · 27 citations · Cited by this paper
  30. The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework · Stephen J. Duffield · 2023 · 27 citations · Cited by this paper
  31. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications · Hoss A. Dowlat · 2016 · 26 citations · Cited by this paper
  32. The global landscape on interchangeability of biosimilars · Anurag Singh Rathore · 2021 · 18 citations · Cited by this paper
  33. Validation of an ICD ‐10 case‐finding algorithm for endometrial cancer in US insurance claims · Djeneba Audrey Djibo · 2023 · 6 citations · Cited by this paper
  34. Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm · Catherine M. Lockhart · 2023 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)